Logo

Because We're Worth It

Aug 15, 2008

Genentech finally came through with its long-expected rejection of Roche's acquisition bid, saying that the asking price "substantially undervalues the company," according to this story in the New York Times. Analysts predict that the companies will continue to negotiate, and that Roche will raise the offer from its original $43.7 billion.

The story also reports that Genentech is prepping to launch an "employee retention program, an indication it was worried that scientists and executives might leave now that the company could lose its independence."

 

Breaking News
The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.